Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

48.41 +0.57 (+1.19%)
Official Closing Price Updated: 7:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
75 76 Next >
Amazon, Alphabet, Meta, Intel Q3 Earnings This Week: Will Mega-Caps Shatter Forecasts And Revive Market?
Factset data indicates that out of the 17% of the S&P 500 companies that have reported so far, 73% have reported positive EPS surprises. 
Via Benzinga
Topics Stocks
Exposures US Equities
What 12 Analyst Ratings Have To Say About Bristol-Myers Squibb
Via Benzinga
3 Things About Bristol Myers Squibb That Smart Investors Know
The stock is down this year, but will its struggles fade into the rearview mirror? 
Via The Motley Fool
2 High-Yield Dividend Stocks to Buy Now
These two blue-chip stocks sport generous yields. 
Via The Motley Fool
Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?
The venerable pharmaceutical companies' shares have slumped this year. 
Via The Motley Fool
Investor Risk Sentiment Wavers Amid War, Interest Rate Concerns; Tesla Earnings Disappoint: The Week In The Markets
In the week ahead, earnings season moves into full swing with reports from companies like Microsoft, Alphabet, Meta Platforms and Amazon. 
Via Benzinga
7 Healthcare Stocks That Can Cure a Lackluster Portfolio
Take a position in these companies' stocks to achieve long-term gains and give a jolt to your investment portfolio. 
Via InvestorPlace
Is Bristol Myers Squibb Stock a Buy Now?
Bristol Myers Squibb recently announced an acquisition that should strengthen its oncology portfolio. 
Via The Motley Fool
Opdivo's Subcutaneous Formulation Shows Promise in Advanced Kidney Cancer: Bristol Myers Squibb's Latest Findings
Bristol Myers Squibb Co (NYSE: BMY) released topline data from the Phase 3 CheckMate -67T noninferiority trial of a subcutaneous Opdivo (nivolumab) compared to intravenous (IV) Opdivo for advanced or... 
Via Benzinga
Could Bristol Myers Squibb Stock Help You Become a Millionaire?
Bristol Myers has been investing in growth, but will it be enough to get investors bullish on its struggling stock? 
Via The Motley Fool
Phase 3 CheckMate -67T Trial of Subcutaneous Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced or Metastatic Clear Cell Renal Cell Carcinoma
From Bristol Myers Squibb
Via Business Wire
The Robert A. Winn Diversity in Clinical Trials Award Announces Third Group of Physicians in Program to Increase Diversity in Clinical Trials
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Highlights Opdivo Regime Data In Lung Cancer Settings
Bristol Myers Squibb & Co (NYSE: BMY) announced the first disclosure of data from the Phase 3 CheckMate -77T trial of the perioperative regimen of neoadjuvant Opdivo (nivolumab) with chemotherapy... 
Via Benzinga
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Provides Benefits for Patients with Resectable Non-Small Cell Lung Cancer Across PD-L1 Expression Levels with Three-Year Follow Up in CheckMate -816 Trial
From Bristol Myers Squibb
Via Business Wire
Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Followed by Opdivo Demonstrates Significant Survival Benefits for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in Phase 3 CheckMate -901 Trial
From Bristol Myers Squibb
Via Business Wire
Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Shows Significant Improvement in Event-Free Survival for Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -77T Trial
From Bristol Myers Squibb
Via Business Wire
2 Biotech Stocks That Could Make You Richer
These two well-known drugmakers still have some growth fuel in their seemingly empty tanks. 
Via The Motley Fool
Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race
Major pharmaceutical companies are continuing to make substantial acquisitions in the field of oncology, sparking enthusiasm in the market. Bristol Myers Squibb (NYSE:BMY) just announced its plan to... 
Via PressReach
FDA Approves Merck's Top Selling Drug, Keytruda For Expanded Use In Lung Cancer Indication
The FDA approved Merck & Co Inc's (NYSE: MRK) Keytruda for resectable (tumors ≥4 centimeters [cm] or node-positive) non-small cell lung cancer (NSCLC) in combination with platinum-containing... 
Via Benzinga
Exposures Product Safety
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq – CNSL), Mirati Therapeutics, Inc.® (Nasdaq - MRTX), Pioneer Natural Resources (NYSE - PXD), Summit Materials (NYSE
From Brodsky & Smith LLC
Via GlobeNewswire
Why Is Alzheimer's Player Prothena Stock Trading Higher Today?
Prothena Corporation plc (NASDAQ: PRTA) is reportedly talking to advisors, potentially preparing for a sale. 
Via Benzinga
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma1
From Bristol Myers Squibb
Via Business Wire
FDA OKs Pfizer's New Bowel Disease Drug, Analysts Predict Peak Sales Of $3B A Year
The Food and Drug Administration (FDA) approved Pfizer Inc's (NYSE: PFE) Velsipity (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with... 
Via Benzinga
Exposures Product Safety
3 Healthcare Stocks To Make You The Millionaire Next Door: October Edition
These are the healthcare stocks to buy as they represent companies investing in research and development for growth and value creation. 
Via InvestorPlace
When you look at NYSE:BMY, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Don't overlook BRISTOL-MYERS SQUIBB CO (NYSE:BMY)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023
From Bristol Myers Squibb
Via Business Wire
Sotyktu (deucravacitinib) Long-Term Data Demonstrate Durable Efficacy and Consistent Safety for up to Three Years in Moderate-to-Severe Plaque Psoriasis
From Bristol Myers Squibb
Via Business Wire
Amgen Stock Surges To 10-Month High, Up 4% On An Unexpected Upgrade
The company has growing pipeline optionality, according to the upgrade report. 
Via Investor's Business Daily
Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis
From Bristol Myers Squibb
Via Business Wire
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
75 76 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.